NasdaqGS - Nasdaq Real Time Price USD

BioNTech SE (BNTX)

93.52

-3.43

(-3.54%)

As of 2:42 PM EDT. Market Open.

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink's TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.

PR Newswire yesterday

BNTX
-3.54%
Why Vaccine Stocks Rallied This Week

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

Motley Fool 4 days ago

MRNA
-9.62%
BNTX
-3.54%
NVAX
-5.87%
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi

GlobeNewswire 7 days ago

BNTX
-3.54%
Q1 2024 Autolus Therapeutics PLC Earnings Call

Q1 2024 Autolus Therapeutics PLC Earnings Call

Thomson Reuters StreetEvents 10 days ago

BNTX
-3.54%
AUTL
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte

Benzinga 10 days ago

MRNA
-9.62%
PFE

BNTX
-3.54%
Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

PREMIUM
MT Newswires 11 days ago

MRNA
-9.62%
PFE

BNTX
-3.54%
Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

PREMIUM
MT Newswires 11 days ago

PFE

BNTX
-3.54%
MRNA
-9.62%
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders. “The past few years marked a leap in competence for BioNTech,” said He

GlobeNewswire 11 days ago

BNTX
-3.54%
We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Key Insights BioNTech will host its Annual General Meeting on 17th of May CEO Ugur Sahin's total compensation includes...

Simply Wall St. 17 days ago

BNTX
-3.54%
BioNTech SE (NASDAQ:BNTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Investors in BioNTech SE ( NASDAQ:BNTX ) had a good week, as its shares rose 2.3% to close at US$90.88 following the...

Simply Wall St. 20 days ago

BNTX
-3.54%
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to BioNTech’s First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria […]

Insider Monkey 21 days ago

BNTX
-3.54%
BioNTech reports net loss of €315.1m in Q1 2024

Total revenues for the quarter saw a substantial decrease to €187.6m from €1.27bn in Q1 2023.

Pharmaceutical Technology 21 days ago

BNTX
-3.54%
Q1 2024 BioNTech SE Earnings Call

Q1 2024 BioNTech SE Earnings Call

Thomson Reuters StreetEvents 21 days ago

BNTX
-3.54%
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come

BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.

Investor's Business Daily 21 days ago

BNTX
-3.54%
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript

BNTX earnings call for the period ending March 31, 2024.

Motley Fool 22 days ago

BNTX
-3.54%
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline

BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline

PREMIUM
MT Newswires 22 days ago

BNTX
-3.54%
What's Going With BioNTech Stock On Monday?

Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker reported sales of 187.6 million euros (roughly $202 million), down from 1.3 billion euros reported a year ago, missing the consensus of 427.5 million euros. The European biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier. “We expect t

Benzinga 22 days ago

BNTX
-3.54%
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales

The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.

Barrons.com 22 days ago

BNTX
-3.54%
PFE
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

Reuters 22 days ago

BNTX
-3.54%
PFE
BioNTech says 90% of 2024 revenues will accrue at end of year

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

Reuters 22 days ago

BNTX
-3.54%
PFE

Performance Overview

Return	BNTX	MSCI WORLD
YTD	-11.39%	+8.96%
1-Year	-11.16%	+22.11%
3-Year	-52.07%	+16.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNTech SE (BNTX)

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

Why Vaccine Stocks Rallied This Week

BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

Q1 2024 Autolus Therapeutics PLC Earnings Call

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

BioNTech SE (NASDAQ:BNTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript

BioNTech reports net loss of €315.1m in Q1 2024

Q1 2024 BioNTech SE Earnings Call

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come

BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript

BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline

What's Going With BioNTech Stock On Monday?

BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales

UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year

BioNTech says 90% of 2024 revenues will accrue at end of year

Performance Overview